Rheumatoid arthritis (RA) is a chronic inflammatory disease, in which pathogenesis many genetic, environmental and hormonal factors have been implicated. Up to date, the known genetic factors account for the 60 % of the genetic basis of the disease. The molecular pathway of autophagy and the related genes have not yet been studied for their role in RA liability. Autophagy has proved to be important in the maintenance of cellular homeostasis and energetic balance, in cellular and tissue remodeling and in cellular defense against extracellular insults and pathogens [1]. In addition, recently, it was reported the role of autophagy and related proteins in human immune responses and inflammatory diseases’ pathogenesis [2, 3]. Therefore, mutations and polymorphisms of autophagic genes could possibly be related to autoimmune diseases’ predisposition such as RA. Specifically, during autophagy, large portions of the cytoplasm as big as whole organelles (e.g., mitochondria) are captured by isolation membranes (phagophores) and sequestered into autophagosomes for degradation within the specialized lytic organelles termed autolysosomes [1]. The genes (Atg) involved in this pathway have been identified in species from yeast to humans, and their variants could be related to diseases’ pathogenesis. Polymorphism rs2241880 in exon 8 of ATG16L1 (autophagy-related 16-like 1) gene results in the amino acid substitution Thr300Ala. This polymorphism has mainly been studied for its association with autoimmune diseases’ susceptibility, and it has been revealed to play a role in Crohn’s disease, ulcerative colitis and palmoplantar pustulosis, while altered expression profiles of ATG16L1 have been described in psoriatic arthritis [4–7]. The aim of the present research protocol was to study the association of ATG16L1 polymorphism rs2241880 with RA liability. One hundred and thirty-four unrelated RA patients, who satisfied the American College of Rheumatology criteria, were enrolled in the study. Additionally, 147 ethnicmatching healthy volunteers with no personal or family history of chronic autoimmune, metabolic or infectious diseases were included in the study [8]. All subjects gave informed written consent in accordance with Helsinki Declaration of 1975/83 and the local ethics committee granted approval. Genomic DNA was extracted from peripheral blood lymphocytes according to the standard salt extraction procedure. ATG16L1 polymorphism rs2241880 was amplified using the following primer pair: rs2241880F: 50-TCA AGC GTG GTA GGG TTC GGG G-30, rs2241880R: 50-CTT CCT TCC CAG TCC CCC AGG-30. Polymerase chain reaction– restriction fragment length polymorphism (PCR–RFLP) assay was conducted using the restriction endonuclease SfaN I. Double digestion of each PCR product was performed so as to confirm the results of the RFLP assay, and no discrepancies between the two digestions were revealed. The SPSS statistical package was used to test differences in polymorphisms’ distribution between RA patients and controls (Pearson’s chi-square). Furthermore, the odds ratio (OR) with a confidence interval (CI) of 95 % was calculated. A difference at p B 0.05 was considered as statistically significant. A. Chatzikyriakidou Laboratory of General Biology and Genetics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Read full abstract